Multiple Sclerosis Market

View All

MedTech News for Allumiqs, MangoRx, Ventris
Allumiqs and Prolytix’s Partnership; Setpoint Medical’s Neuroimmune Modulation Platform gets FDA Breakthrough Designation; MangoRx Launches ‘PRIME’ with FDA-approved TRT; SeaStar Medical Updates Quelimmune Commercial Launch; Ventris Medical Gains 510(k) for Amplify® Bone Graft Putty

MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment On March 12, 2024, Mangoceuticals, Inc. unveiled a groundbreaking development eagerly awaited by many: the launch of 'PRIME' by MangoRx, Powered by Kyzatrex®️. This release mar...

Find More

multiple-sclerosis-treatment
Revolutionizing Multiple Sclerosis Treatment: A New Era of Therapies

Multiple sclerosis is an unpredictable, autoimmune disease that affects the central nervous system. Multiple sclerosis is believed to impact almost 1 million Americans, and the disease manifests itself in a variety of ways. Because nerves are affected in different ways and exhibit a variety of symptoms, no two case...

Find More

Multiple-Sclerosis
World Multiple Sclerosis Day

Multiple Sclerosis Multiple Sclerosis is an unpredictable, autoimmune disease that affects the central nervous system. In this disease, the body's own immune system produces cells and proteins (antibodies), which attack the fatty substance,myelin that protects the nerve fibres. So, 30 May 2019 is globally obser...

Find More

Multiple Sclerosis
Beta Interferons prolongs life in Multiple Sclerosis

Multiple Sclerosis is an unpredictable, autoimmune disease that affects the central nervous system, disrupting the transfer of information within, or between the brain and body. It causes the body’s immune system to produce cells and proteins (antibodies) that attack the fatty substance, myelin, which is responsibl...

Find More

Mylan closing Illinois plant; Insys spends $24M; Roche’s Ocrevus; Greece’s corruption prosecutor quits

Mylan closing Illinois plant, cutting 90 jobs as part of slim-down after Meda buyout Mylan has been in the midst of cutting about 3,500 jobs to decrease costs and refocus after its $7 billion buyout last year of Meda Pharmaceuticals. About 90 of those cuts will come with the closure of a plant in Illinois.The drugma...

Find More